Home › Trials › NCT07063680
Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 18 and up

Early argipressin for adults with norepinephrine‑refractory vasoplegic shock

Official title: Efficacy of Early Argipressin (Arginine Vasopressin) in the Management of Intensive Care Patients With Norepinephrine-refractory Vasoplegic Shock: a Multicentric Randomized, Double-blind Placebo-controlled Superiority Trial

Run by Centre Hospitalier Universitaire Dijon · NCT07063680 · Data updated 2026-11-12

This trial will test whether giving argipressin early helps adults in the ICU whose vasoplegic shock does not respond to high‑dose norepinephrine.

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment390 (estimated)
SponsorCentre Hospitalier Universitaire Dijon
Academic / other
Locations1 site (Dijon)
StatusRecruiting
StartedApril 7, 2026
Main results expectedJanuary 2029
Study endsJanuary 2029
Registry record updatedApril 14, 2026
Trial IDNCT07063680 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18 years) in the ICU with vasoplegic shock from causes such as sepsis, post‑operative vasoplegia, hemorrhage, sterile inflammation, anaphylaxis, or liver failure who have cardiac index ≥ 2.3 L/min/m², lactate > 2 mmol/L, require ≥ 0.25 µg/kg/min norepinephrine‑equivalent, and have been in refractory shock for under 12 hours.

Probably not a fit

Patients who do not meet the cardiac index or vasopressor thresholds, those with low‑output or primarily cardiogenic shock rather than vasoplegia, those already beyond 12 hours of refractory shock, or with contraindications to vasopressin may not receive benefit from this approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 interventional trial enrolls adults with vasoplegic shock who remain hypotensive despite high‑dose norepinephrine and meet objective hemodynamic criteria. Eligible patients must have a cardiac index ≥ 2.3 L/min/m², lactate > 2 mmol/L, require a norepinephrine‑equivalent dose ≥ 0.25 µg/kg/min, and have met refractory shock criteria for less than 12 hours. Participants receive argipressin in addition to standard ICU care while clinical data on hemodynamics, organ function, vasopressor exposure, and outcomes are collected. The trial is led by CHU Dijon Bourgogne and focuses on early second‑line vasopressin use in catecholamine‑refractory vasoplegia.

Why it matters

Potential benefit: If successful, early argipressin could speed shock reversal, reduce exposure to high‑dose catecholamines, and protect organ function such as the kidneys.

How similar studies have gone: Previous randomized and observational studies of vasopressin in catecholamine‑refractory vasoplegia and septic shock have shown mixed results with some vasopressor‑sparing and renal benefits but no consistent mortality advantage, so larger Phase 3 data are needed.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patients aged ≥ 18 years
* Vasoplegic shock defined as patient requiring vasopressor at the time of inclusion AND with a cardiac index ≥ 2.3/L/min/m² \[32\] (measured by echocardiography, Swan-Ganz, pulse contour analysis or thermodilution) and with hyperlactatemia \> 2 mmol/l.
* Vasoplegia must be primarily caused by one of the following etiologies:

  * Sepsis (documented or clinically suspected infection)
  * Post-operative vasoplegia (following cardiac or non-cardiac surgery)
  * Post hemorrhage
  * Sterile systemic inflammation (e.g., pancreatitis, burns, trauma)
  * Anaphylaxis
  * Liver failure
  * Other causes of vasoplegia
* Refractory shock: dose of vasopressor (express as norepinephrine base equivalent) ≥ 0.25 μg/kg/min in order to maintain perfusion pressure within patient-defined targets (defined by the physician in charge of the patient).
* Early intervention: Criteria for refractory AND vasoplegic shock reached for less than 12 hours.
* Informed consent obtained from the patient or, if unable to give consent, a surrogate. If the surrogate is not available, emergency consent can be considered.
* Covered by French national health insurance

Exclusion Criteria:

* Patients that do not present the criteria for vasoplegic AND refractory shock at the time of inclusion anymore (resolved condition)
* Ongoing vasopressin treatment
* Ongoing inotrope treatment (except norepinephrine)
* Ongoing acute coronary syndrome, mesenteric ischemia
* Uncontrolled active bleeding
* Vasoplegia due to neurogenic shock
* Vasospastic disease (Raynaud's disease, systemic scleroderma…)
* Hyponatremia \<120 mmol l-1
* Known hypersensitivity to Argipressin or to any of the excipients of REVERPLEG®.
* Patient already enrolled in an interventional trial
* Decision to limit life-sustaining treatments
* Person under legal protection
* Pregnant, parturient or breastfeeding women

Where it's running

  • CHU Dijon Bourgogne
    Dijon, France     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Centre Hospitalier Universitaire Dijon 87
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.